Nationwide rates for lung screening remain in the single digits—as low as 2% according to 2018 research from the American Society of Clinical Oncology. For imaging programs and health systems, these rates should signal that low-dose lung screening is a growth opportunity. Not only can programs benefit from the immediate revenue of additional low-dose CT screening exams, but lung screening programs can generate significant downstream revenue for the system and save overall health care spending by catching cancers early. However, there are a few key barriers to growth for lung screening programs: